CanFinis Pipeline

Advanced CAR-T Product

Canfinis Therapeutics stands out with its Advanced CAR-T Product, poised for a potential gastro-intestinal cancer clinical trial soon, demonstrating our ability to rapidly bring cutting-edge therapies to market. In addition, our robust pipeline includes 4 other CAR-T products in various stages of development, showcasing a diverse and expanding portfolio. This unique combination of clinical readiness and pipeline depth represents a significant value addition and solidifies the company’s position as a high-potential player in the CAR-T space. These assets provide us with both near-term and long-term growth opportunities.

Canfinis Pipeline
Product Description 2025 2026 2027 2028
CF-003 CAR-Ts for Metastatic Gastric Cancers Manufacturing & Phase I Phase II Approval Commercial
CF-005 CAR-Ts for Primary Gastric Cancers Preclinical Manufacturing Phase I & Phase IIa
CF-007 CAR-Ts for other metastatic cancer in the peritoneal cavity Early Preclinical Preclinical Manufacturing
CF-009 CAR-Ts for Mesothelioma & Lung cancer Target Selection Discovery and Lead IDs Preclinical POC
CF-011 CAR-Ts for Metastatic Prostate cancer Target Selection Discovery and Lead IDs Preclinical POC

Canfinis Pipeline